Related Experiment Videos
Mivacurium-induced prolonged neuromuscular block
1Department of Anaesthesia, King's College Hospital, Denmark Hill, London.
British Journal of Anaesthesia
|February 1, 1995
Summary
A patient with atypical plasma cholinesterase deficiency experienced a prolonged neuromuscular block from mivacurium, lasting 2.5 hours. This occurred despite normal responses to suxamethonium, highlighting a unique drug interaction in this genetic condition.
Area of Science:
- Anesthesiology
- Pharmacology
- Genetics
Background:
- Neuromuscular blocking agents are crucial in anesthesia.
- Plasma cholinesterase is essential for metabolizing certain muscle relaxants.
- Genetic variations in plasma cholinesterase can affect drug metabolism and duration of action.
Observation:
- A 16-year-old patient developed a 2.5-hour neuromuscular block after receiving mivacurium.
- The patient had homozygous atypical plasma cholinesterase deficiency.
- Despite the deficiency, the patient showed normal responses to suxamethonium on two prior occasions.
Findings:
- The patient exhibited significantly reduced plasma cholinesterase activity (343 iu litre-1) and a low dibucaine number (25).
- Atypical plasma cholinesterase, typically associated with prolonged suxamethonium block, did not affect this patient's response to suxamethonium.
- Mivacurium administration resulted in a markedly prolonged neuromuscular block, directly linked to the patient's atypical plasma cholinesterase.
Implications:
- This case highlights a specific pharmacogenetic interaction between mivacurium and atypical plasma cholinesterase.
- It suggests that atypical plasma cholinesterase deficiency may manifest differently with various neuromuscular blocking agents.
- Further research is needed to understand the precise mechanisms and clinical implications for anesthetic practice.